In the NEOMONARCH 2 trial, 223 postmenopausal ER+ HER2 negative with clinical stage I-III breast cancer patients were randomized to receive anastrozole monotherapy, abemaciclib monotherapy or their combination. The gene discussed is ESR1; the disease is breast cancer.